A Pfizer Inc. subsidiary has ended its decade-old dispute with Teva Pharmaceuticals USA Inc. over the hypertension drug Accupril by dropping attorneys' fees and willful infringement claims in exchange for Teva dropping its appeal of a finding that the generics maker infringed Pfizer's patent.
The details can be read here.
No comments:
Post a Comment